NP
NPHC.US Nutra Pharma Corp
- Market cap
- USD 1.43M
- P/E
- -
- P/B
- 46.56x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NPHC.US undervalued?
Graham numberThe Graham number of Nutra Pharma Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nutra Pharma Corp fundamental analysis
No fundamental analysis for Nutra Pharma Corp yet.
Nutra Pharma Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nutra Pharma Corp
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, non"narcotic, non"addictive, over"the"counter pain reliever to treat moderate to severe chronic …
Full company profileNutra Pharma Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nutra Pharma Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 168K | 121K | -1.88M | 104K | 104K | 97.7K | 438K | 595K | 392K | 385K | 165K |
| Gross Profit | -54.6K | 94.1K | 14.1K | 34.7K | 34.7K | 8.47K | 249K | 396K | 247K | 197K | 103K |
| Operating Income | 2.04M | -1.38M | -1.88M | -1.23M | -1.17M | -1.92M | -1.84M | -782K | -878K | -1.46M | -1.63M |
| EBITDA | -3.15M | -3.66M | -3.29M | -6.25M | -6.25M | -12.5M | 9.08M | -898K | -871K | -1.36M | -1.62M |
| Net Income | -3.45M | -4.03M | -3.88M | -6.59M | -6.59M | -13.1M | 8.18M | -1.39M | -1.29M | -2.05M | -8.82M |
| EPS | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 214K | 390K | 141K | 340K | 141K | 780K | 755K | 640K | 599K | 585K | 623K |
| Total Liabilities | 4.69M | 5.80M | 6.08M | 12.0M | 6.08M | 21.7M | 13.1M | 14.4M | 15.4M | 17.4M | 21.8M |
| Shareholders' Equity | -4.48M | -5.41M | -5.94M | -11.7M | -5.94M | -20.9M | -12.4M | -13.8M | -14.8M | -16.8M | -21.2M |
| Cash & Short-term Investments | 31.2K | 0.00 | 0.00 | 0.00 | -217K | 90.9K | 0.00 | 0.00 | 36.4K | 29.8K | 17.6K |
| Total Debt | 2.63M | 3.47M | - | - | 4.43M | 8.20M | - | - | - | 9.76M | 12.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.36M | -1.14M | -1,000K | -744K | -744K | -1.74M | -762K | -550K | -424K | -1.16M | -1.16M |
| Capital Expenditure | 3.38K | 9.11K | 5.91K | 5.91K | 5.91K | 39.0K | 58.0K | 0.00 | 0.00 | 26.1K | 4.00 |
| Free Cash Flow | -1.36M | -1.15M | -1,000K | -744K | -744K | -1.78M | -820K | -550K | -424K | -1.19M | -1.16M |
| Ratios | |||||||||||
| ROA | -1,609.1% | -1,034.2% | -2,747.0% | -1,939.6% | -4,661.0% | -1,678.9% | 1,083.2% | -217.6% | -214.5% | -350.2% | -1,415.5% |
| Net Profit Margin | -2,047.8% | -3,330.1% | - | -6,314.1% | -6,314.1% | -13,399.0% | 1,865.7% | -234.2% | -327.8% | -531.4% | -5,332.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nutra Pharma Corp dividends
Nutra Pharma Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on May 18, 2015.
Who owns Nutra Pharma Corp
- Insiders 1.02%
- Institutions 0.00%
- Public & others 98.98%
- Shares outstanding 7.16B
- Free float 7.09B
Nutra Pharma Corp company profile
- Company name
- Nutra Pharma Corp
- Ticker
- NPHC.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 6400 Park of Commerce Blvd, Boca Raton, FL, United States, 33487
- Phone
- 954 509 0911
- Website
- nutrapharma.com
About Nutra Pharma Corp
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, non"narcotic, non"addictive, over"the"counter pain reliever to treat moderate to severe chronic pain in companion animals; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxury Feet, an OTC pain reliever for foot pain from high heels and stilettos. It is also involved in developing RPI-78M to treat neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, and general anti -viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Boca Raton, Florida.
Nutra Pharma Corp management
4- Dr. Michael D. Flax D.D.S., M.S., P.A.President, CEO, CFO & Chairman · born 1956
- Dr. Dale Vander Putten MBA, Ph.D.Chief Scientific Officer · born 1959
- Joe LucasVice President of Operations
- Ms. Nina GoldsteinSecretary · born 1960